Sugi Predict

Sugi Predict / Compounds / SCHEMBL938437

SCHEMBL938437

SCHEMBL938437

FC(F)(Cl)c1nnc2ccc(Br)cn12

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ KDM4E B2RXH2 2/20 0.47
▸ SCN5A Q14524 11/20 0.45
▸ SCN1A P35498 1/20 0.41
▸ SCN2A Q99250 1/20 0.41
▸ ALDH1A1 P00352 3/20 0.38
▸ MET P08581 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ GAA P10253 1/20 0.36
▸ TSHR P16473 1/20 0.36
▸ MAPK10 P53779 1/20 0.36
▸ AHR P35869 1/20 0.35
▸ MEN1 O00255 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ RECQL P46063 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ RXFP1 Q9HBX9 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL667109 0.87 SCN5A (0.58) SMN1; SMN2KDM4ESCN5ASCN1ASCN2A
SCHEMBL23116008 0.81 SCN5A (0.48) SMN1; SMN2KDM4ESCN5ASCN1ASCN2A
SCHEMBL1159892 0.80 SCN5A (0.41) SMN1; SMN2KDM4ESCN5ASCN1ASCN2A
SCHEMBL4212574 0.80 SCN5A (0.46) SCN5ASCN1ASCN2AMETGAA
SCHEMBL251679 0.78 SMN1; SMN2 (0.41) SMN1; SMN2KDM4ESCN5ASCN1ASCN2A
SCHEMBL23116011 0.77 SCN5A (0.41) SCN5ASCN1ASCN2AALDH1A1MET
SCHEMBL938219 0.77 SCN5A (0.44) SCN5ASCN1ASCN2AMETGAA
SCHEMBL23116199 0.77 SCN5A (0.41) KDM4ESCN5ASCN1ASCN2AMET
SCHEMBL23116248 0.76 SCN5A (0.38) SMN1; SMN2KDM4ESCN5ASCN1ASCN2A
SCHEMBL251334 0.75 SCN5A (0.37) SMN1; SMN2KDM4ESCN5ASCN1ASCN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376475-A1 ION CHANNEL MODULATORS PRAXIS PREC MEDICINES INC (US) 2025-12-11 — — US disclosed
CN-119371426-A Ion channel modulators 普拉克西斯精密药物股份有限公司 2025-01-28 — — CN disclosed
CN-119350320-A Ion channel modulators 普拉克西斯精密药物股份有限公司 2025-01-24 — — CN disclosed
EP-4487916-A2 ION CHANNEL MODULATORS Praxis Precision Medicines, Inc. (US) 2025-01-08 — — EP disclosed
US-20240132501-A1 ION CHANNEL MODULATORS PRAXIS PRECISION MEDICINES, INC. (US) 2024-04-25 — — US disclosed
US-11866439-B2 Ion channel modulators PRAXIS PRECISION MEDICINES, INC. (US) 2024-01-09 — — US disclosed
US-11731978-B2 3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine as an ion channel modulator PRAXIS PRECISION MEDICINES, INC. (US) 2023-08-22 — — US disclosed
US-11731978-B2 3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine as an ion channel modulator PRAXIS PRECISION MEDICINES, INC. (US) 2023-08-22 — — US disclosed
US-11731976-B2 3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine as an ion channel modulator PRAXIS PRECISION MEDICINES, INC. (US) 2023-08-22 — — US disclosed
US-11731976-B2 3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine as an ion channel modulator PRAXIS PRECISION MEDICINES, INC. (US) 2023-08-22 — — US disclosed
US-20140303158-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD SCIENCES, INC. (US) 2014-10-09 — — US disclosed
US-8754103-B2 — — 2014-06-17 — — US disclosed
US-8754103-B2 — — 2014-06-17 — — US disclosed
US-8754103-B2 — — 2014-06-17 — — US disclosed
EP-2464645-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS Gilead Palo Alto, Inc. (US) 2012-06-20 — — EP disclosed
WO-2011014462-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2011-02-03 — — WO disclosed
WO-2011014462-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2011-02-03 — — WO disclosed
US-20110021521-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2011-01-27 — — US disclosed
US-20110021521-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2011-01-27 — — US disclosed
US-20110021521-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2011-01-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11731978-B2 3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine as an ion channel modulator SCN1A, SCN3A, CACNA1F SMN1; SMN2 161/4885KDM4E 1179/4885SCN5A 8/4885
US-20240132501-A1 ION CHANNEL MODULATORS SCN1A, SCN3A, SCN2A SMN1; SMN2 185/4885KDM4E 2324/4885SCN5A 5/4885
US-11731976-B2 3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine as an ion channel modulator SCN1A, SCN3A, CACNA1F SMN1; SMN2 163/4885KDM4E 1111/4885SCN5A 8/4885
US-11866439-B2 Ion channel modulators SCN1A, SCN3A, SCN2A SMN1; SMN2 185/4885KDM4E 2324/4885SCN5A 5/4885
US-20140303158-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS KCNJ2, KCNH2, KCNA3 SMN1; SMN2 1673/4885KDM4E 2541/4885SCN5A 52/4885
US-20110021521-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS KCNJ2, KCNH2, KCNA3 SMN1; SMN2 1673/4885KDM4E 2541/4885SCN5A 52/4885
US-20250376475-A1 ION CHANNEL MODULATORS SCN1A, SCN3A, SCN2A SMN1; SMN2 185/4885KDM4E 2324/4885SCN5A 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.